Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Non-Current Debt (2021 - 2023)

Standard Biotools (LAB) has disclosed Non-Current Debt for 5 consecutive years, with $3.4 million as the latest value for Q4 2023.

  • On a quarterly basis, Non-Current Debt fell 58.34% to $3.4 million in Q4 2023 year-over-year; TTM through Dec 2023 was $3.4 million, a 58.34% decrease, with the full-year FY2023 number at $3.4 million, down 58.34% from a year prior.
  • Non-Current Debt was $3.4 million for Q4 2023 at Standard Biotools, down from $4.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $10.2 million in Q2 2022 to a low of $3.4 million in Q4 2023.
  • A 3-year average of $7.9 million and a median of $8.8 million in 2022 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: dropped 6.07% in 2022, then plummeted 58.34% in 2023.
  • Standard Biotools' Non-Current Debt stood at $10.0 million in 2021, then dropped by 18.46% to $8.2 million in 2022, then crashed by 58.34% to $3.4 million in 2023.
  • Per Business Quant, the three most recent readings for LAB's Non-Current Debt are $3.4 million (Q4 2023), $4.6 million (Q3 2023), and $5.8 million (Q2 2023).